Fourteen patients with longstanding lipodermatosclerosis of their lower legs, secondary to venous disease in 11, were treated for three months with stanozolol, a drug that enhances fibrinolytic activity. No other treatment was given and no change made in existing treatment. All the patients improved. Two were cured in three months, three were able to stop treatment in the next three to 11 months, and the other nine continued to improve. Fibrinolytic enhancement, with stanozolol, seems to be a worthwhile addition to the treatment of venous liposclerosis and deserves further study.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1631172 | PMC |
| http://dx.doi.org/10.1136/bmj.2.6084.434 | DOI Listing |
Publication Analysis
Top Keywords
three months
12
fibrinolytic enhancement
8
treatment
5
treatment liposclerosis
4
liposclerosis leg
4
leg fibrinolytic
4
enhancement preliminary
4
preliminary report
4
report fourteen
4
fourteen patients
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!